Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trastuzumab biosimilar EG12014
- Development stage
- Phase 3
- Lead developer
- EirGenix
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Vaccines & Immunotherapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
EG12014 is a biosimilar of trastuzumab, a recombinant humanized IgG1 monoclonal antibody that targets the human epidermal growth factor receptor 2 (HER2/ERBB2). It is developed for the treatment of HER2-positive breast cancer and metastatic gastric cancer. EG12014 binds to the extracellular domain of the HER2 receptor on tumor cells and inhibits proliferation by blocking downstream signaling pathways involved in cell growth and survival. The drug has demonstrated equivalent efficacy and safety to reference trastuzumab in clinical trials. Developed by EirGenix with Sandoz as commercial partner, it has received marketing authorization from the European Commission for use in these indications and market approval in Taiwan[1][2][4][6].
- Brand names
- HerwendaEIRGASUN
- Other names
- trastuzumab biosimilar-EirGenixtrastuzumab biosimilar
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on trastuzumab biosimilar EG12014.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trastuzumab biosimilar EG12014.